Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Of the title character in “Lost Evangeline,” it is said she “lived a great life of the imagination.” You could say the same about Evangeline’s creator, Kate DiCamillo. The beloved, Minneapolis-based ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...

As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders. The Big Pharma had been running three midstage studies of the ...

is an experienced journalist with a diverse background in reporting, anchoring, and digital media. CORPUS CHRISTI, Texas — A proposed brackish groundwater deal that once appeared affordable is now ...

Eli Lilly is pivoting its pain pipeline, punting a midstage program it licensed from Centrexion Therapeutics while adding a candidate from its recent SiteOne Therapeutics buyout to its early-phase ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company is moving to offload another plant with a checkered past. Lilly plans to ...

Helena’s proprietary day scores give the odds for a day for everyone. Higher scores = more opportunity. Lower scores = more risk. Range = +2500 to –2500. BIRTHDAY STAR: Actor Evangeline Lilly was born ...